Insider Selling: CeriBell (NASDAQ:CBLL) CEO Sells $145,753.36 in Stock

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 6,068 shares of the stock in a transaction on Friday, August 21st. The stock was sold at an average price of $24.02, for a total value of $145,753.36. Following the transaction, the chief executive officer owned 781,731 shares of the company’s stock, valued at $18,777,178.62. The trade was a 0.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Xingjuan Chao also recently made the following trade(s):

• On Wednesday, August 19th, Xingjuan Chao sold 31,415 shares of CeriBell stock. The stock was sold at an average price of $25.03, for a total value of $786,317.45.
• On Tuesday, August 18th, Xingjuan Chao sold 2,199 shares of CeriBell stock. The stock was sold at an average price of $25.00, for a total value of $54,975.00.
• On Tuesday, July 7th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $19.90, for a total value of $776,100.00.
• On Monday, June 8th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The stock was sold at an average price of $18.33, for a total transaction of $714,870.00.

CeriBell Stock Performance

CBLL traded up $0.01 during midday trading on Tuesday, reaching $23.95. The company had a trading volume of 243,381 shares, compared to its average volume of 457,237. The company has a market cap of $919.20 million, a P/E ratio of -13.61 and a beta of 0.81. CeriBell, Inc. has a 1 year low of $10.85 and a 1 year high of $25.33. The business has a 50-day moving average of $19.77 and a two-hundred day moving average of $19.27. The company has a quick ratio of 8.79, a current ratio of 9.18 and a debt-to-equity ratio of 0.16.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%.The firm had revenue of $28.10 million during the quarter, compared to the consensus estimate of $27.28 million. As a group, equities research analysts predict that CeriBell, Inc. will post -1.96 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on CBLL shares. Canaccord Genuity Group boosted their price target on shares of CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Weiss Ratings raised shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. BTIG Research boosted their price target on shares of CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, August 18th. Finally, Barclays raised shares of CeriBell to a “neutral” rating in a research note on Tuesday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $22.40.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CBLL. BlackRock Inc. acquired a new position in shares of CeriBell in the 2nd quarter valued at $37,657,000. Bank of New York Mellon Corp increased its position in shares of CeriBell by 1,945.9% during the fourth quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock valued at $26,797,000 after acquiring an additional 1,162,200 shares during the last quarter. KCM Capital Inc acquired a new position in shares of CeriBell in the 4th quarter worth approximately $21,930,000. TimesSquare Capital Management LLC acquired a new position in CeriBell during the second quarter worth $15,182,000. Finally, Royce & Associates LP purchased a new position in shares of CeriBell during the fourth quarter worth $11,695,000.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.